Hua Y, Keep R F, Hoff J T, Xi G
Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109-2200, USA.
Acta Neurochir Suppl. 2008;105:3-6. doi: 10.1007/978-3-211-09469-3_1.
Intracerebral hemorrhage (ICH) is a subtype of stroke with very high mortality. Experiments have indicated that clot lysis and iron play an important role in ICH-induced brain injury. Iron overload occurs in the brain after ICH in rats. Intracerebral infusion of iron causes brain edema and neuronal death. Deferoxamine, an iron chelator, is an FDA-approved drug for the treatment of acute iron intoxication and chronic iron overload due to transfusion-dependent anemia. Deferoxamine can rapidly penetrate the blood-brain barrier and accumulate in the brain tissue in significant concentration after systemic administration. We have demonstrated that deferoxamine reduces ICH-induced brain edema, neuronal death, brain atrophy, and neurological deficits. Iron chelation with deferoxamine could be a new therapy for ICH.
脑出血（ICH）是一种死亡率极高的中风亚型。实验表明，血凝块溶解和铁在脑出血所致脑损伤中起重要作用。大鼠脑出血后大脑会发生铁过载。脑内注入铁会导致脑水肿和神经元死亡。去铁胺是一种铁螯合剂，是一种经美国食品药品监督管理局（FDA）批准用于治疗急性铁中毒和因输血依赖型贫血导致的慢性铁过载的药物。去铁胺可迅速穿透血脑屏障，全身给药后能在脑组织中大量蓄积。我们已证明，去铁胺可减轻脑出血所致的脑水肿、神经元死亡、脑萎缩和神经功能缺损。用去铁胺进行铁螯合可能是一种治疗脑出血的新疗法。
